龐貝氏症：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 德國龐貝氏症市場預計將從 2025 年的 7,400 萬美元成長到 2035 年的 1.85 億美元，這表明在預測期內市場將大幅擴張。
• 推動市場成長的因素如下：
• 提高晚髮型龐貝氏症患者的診斷和治療率。
• 先進且昂貴的酵素替代療法的應用日益普及
• 提高患者存活率和長期疾病管理
• 未來的市場擴張將主要取決於能夠改善長期功能結果、減輕治療負擔和解決進行性肌肉萎縮問題的創新。

龐貝氏症概述

龐貝氏症是一種罕見的體染色體隱性遺傳進行性溶小體儲積症症，由GAA基因編碼的酸性α-葡萄Glucosidase酶（GAA）缺乏所引起。此病中，病理性溶酶體內肝醣主要在骨骼肌、心肌和平滑肌中積聚，導致不可逆的細胞損傷和器官功能障礙。疾病的嚴重程度與殘餘GAA酶活性呈負相關，臨床表現多樣，從典型的嬰兒型龐貝氏症（出生後數月內出現肥厚型心肌病、嚴重肌張力低下和呼吸衰竭，如不治療迅速致命）到遲髮型龐貝病（兒童和成年期出現進行性進行性肌病和呼吸衰竭，但心臟功能通常保持正常）。診斷首先使用乾血斑檢測GAA酶活性作為初步篩檢手段，然後透過GAA基因定序和肌肉切片檢查證實溶酶體內肝醣的積聚來確診。酵素替代療法（Glucosidaseα）已成為治療的基礎，但Glucosidaseα聯合藥理學Chaperone米格魯司他則代表著一項重大進展，與標準酶替代療法相比，該療法在糖原清除率和臨床功能改善方面均表現出更優的療效。透過肺功能檢查、夜間氧飽和度監測以及包括非侵入性通氣在內的呼吸支持來監測呼吸功能是治療管理的關鍵支柱。物理治療和多學科復健可最佳化功能能力。早期治療，特別是新生兒篩檢計畫的發展，顯著改善了預後。以患者為中心的照護、遺傳諮詢和心理社會支持對於疾病的長期管理至關重要。

主要亮點

• 德國的龐貝氏症患者人數預計將從 2025 年的 1401 人增加到 2035 年的 1510 人，這反映了診斷技術的進步和患者生存率的逐步提高。
• 德國各地對罕見疾病的認知不斷提高，基因檢測的準確性不斷提高，罕見疾病篩檢計畫的擴大，使得罕見疾病的診斷越來越早。
• 目前，酵素替代療法 (ERT) 是主要的治療方法，但人們對療效和組織滲透性較好的下一代治療方法越來越感興趣。
• 目前仍缺乏能夠解決長期肌肉萎縮、呼吸功能下降以及對現有 ERT 療法反應差異等問題的持續治療方案。
• 基因療法和增強型 GAA 替代療法等目前正在研發的治療方法有望徹底改變未來的治療模式。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Genzyme, a Sanofi Company
• Shionogi
• AskBio Inc.
• Amicus Therapeutics
• GeneCradle Inc.
• Astellas Gene Therapies

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求及其未來透過新興治療方法實現的可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Pompe Disease Market Outlook

Thelansis's "Pompe Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pompe Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pompe Disease Overview

Pompe disease is a rare, progressive autosomal recessive lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA) - encoded by the GAA gene - resulting in pathological intralysosomal glycogen accumulation predominantly within skeletal, cardiac, and smooth muscle, causing irreversible cellular damage and organ dysfunction. Disease severity correlates inversely with residual GAA enzyme activity, producing a clinical spectrum ranging from classic infantile-onset Pompe disease - presenting within months of birth with hypertrophic cardiomyopathy, profound hypotonia, respiratory failure, and rapidly fatal course without treatment - to late-onset disease manifesting with progressive proximal myopathy, respiratory insufficiency, and preserved cardiac function across childhood or adulthood. Diagnosis integrates dried blood spot GAA enzyme activity assay as the primary screening tool, confirmed by GAA gene sequencing and muscle biopsy demonstrating lysosomal glycogen accumulation. Enzyme replacement therapy - alglucosidase alfa - established the therapeutic foundation, while cipaglucosidase alfa combined with the pharmacological chaperone miglustat represents a significant advancement, demonstrating superior glycogen clearance and clinically meaningful functional improvements over standard ERT. Respiratory surveillance with pulmonary function testing, nocturnal oximetry, and ventilatory support - including non-invasive ventilation - are critical management pillars. Physiotherapy and multidisciplinary rehabilitation optimise functional capacity. Prognosis has improved substantially with early treatment initiation, particularly through newborn screening programmes; patient-centred care, genetic counselling, and psychosocial support are integral to long-term disease management.

Key Highlights

• In Germany, Pompe Disease prevalent cases are projected to increase from 1,401 patients in 2025 to 1,510 patients in 2035, reflecting gradual improvement in diagnosis and patient survival.
• Increasing awareness, improved genetic testing, and expansion of rare disease screening programs are supporting earlier diagnosis across Germany.
• Current treatment landscape is primarily dominated by enzyme replacement therapies (ERTs), with growing focus on next-generation therapies offering improved efficacy and tissue penetration.
• Persistent unmet need exists for durable treatment options capable of addressing long-term muscle degeneration, respiratory decline, and variable response to existing ERTs.
• Emerging pipeline therapies, including gene therapies and enhanced GAA replacement approaches, are expected to reshape the future treatment paradigm.

Market Overview

• The Germany Pompe Disease market is projected to grow from USD 74 million in 2025 to USD 185 million by 2035, indicating substantial market expansion over the forecast period.
• Market growth is driven by:
• Increasing diagnosis and treatment rates among late-onset Pompe Disease patients
• Rising adoption of advanced and premium-priced enzyme replacement therapies
• Improved patient survival and long-term disease management
• Future market expansion will largely depend on innovations that improve long-term functional outcomes, reduce treatment burden, and address progressive muscle deterioration.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Genzyme, a Sanofi Company
• Shionogi
• AskBio Inc.
• Amicus Therapeutics
• GeneCradle Inc.
• Astellas Gene Therapies

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)